Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy.
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
09 12 2020
09 12 2020
Historique:
received:
05
10
2019
revised:
17
03
2020
accepted:
02
09
2020
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
24
6
2021
Statut:
ppublish
Résumé
REVERSE is a randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial that evaluated the efficacy of a single intravitreal injection of rAAV2/2-
Identifiants
pubmed: 33298565
pii: 12/573/eaaz7423
doi: 10.1126/scitranslmed.aaz7423
pii:
doi:
Substances chimiques
NADH Dehydrogenase
EC 1.6.99.3
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : G0701386
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1002570
Pays : United Kingdom
Informations de copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.